Teva’s New Global Specialty Medicines Unit To Be Led By Koremans
This article was originally published in The Pink Sheet Daily
Executive Summary
Brought in from Sanofi in 2012 as president and CEO of Teva Europe, Rob Koremans now will head a new Global Specialty Medicines unit that CEO Jeremy Levin expects to complement Teva’s generics business. Levin spoke of establishing a “single, differentiated Teva presence” in each market through the two units working together.